Test Selection and Interpretation Guide

Welcome to the Test Selection and Interpretation Guide. This Guide provides information relating to test selection, utilization, and interpretation. The Guide is continually updated by adding new information and modifying posted information. All information is based on peer-reviewed publications, practice guidelines, or other reputable sources and is intended to be without promotional considerations.

Reference ranges are provided for your convenience and are based on Quest Diagnostics data or published references (where cited). These ranges can serve as a guideline; however, interpretation of patient results should be based on the ranges provided in the patient report.

Included in the Test Selection and Interpretation Guide are four types of information:

•

Test highlights and summaries provide a review of clinical use and background, methodology, specimen requirements, and interpretation of the test.

•

Test guides provide testing algorithms or other information that assists in appropriate test selection.

•

Technology guides compare multiple technologies provided for the same or similar analytes.

•

What's New

•

The Acute Myeloid Leukemia (AML): Laboratory Evaluation test guide provides guidance on the use of laboratory testing in the diagnosis, classification, prognosis, and management of AML.

•

Lynch Syndrome an autosomal dominant disease, is characterized by a high lifetime risk of cancers including colorectal cancer, other gastrointestinal cancers, and endometrial and ovarian cancer. Early diagnosis and initiation of surveillance are critical for patients and their family members.

•

The OraRisk^® HPV test can be used to assess risk of oral cancer, especially in people with a prior oral HPV infection, multiple sexual partners, and other high-risk sexual behaviors.

•

The Herpes Simplex Virus, Type 1/2 DNA, Real-Time PCR can be used to diagnose genital infection with herpes simplex virus type 1 or type 2. Both vaginal swab and ThinPrep^® Pap specimens are accepted for this test.

•

The Aspirin Resistance (11-Dehydrothromboxane B2) test can be used to diagnose aspirin resistance in certain patients on low-dose aspirin therapy.

•

The SMA Carrier Screen is a genetic test that can detect carriers of spinal muscular atrophy (SMA), an autosomal recessive disease that causes progressive muscle wasting and weakness due to loss of motor neurons in the spinal cord.